Cellectis files $115M IPO to fund unique CAR-T program

The CAR-T competition is heating up as Cellectis, based in Paris, brings a new approach to cancer immunotherapy using allogeneic treatments.

By Nicole Gray • Feb. 22, 2015

UPDATE: Valeant to buy Salix for $10.1B, cleared for $495M Dendreon buyout

And company CEO Michael Pearson said on Monday that smaller deals are still on the horizon.

By Sy Mukherjee • Feb. 20, 2015

UPDATE: Bayer HealthCare chief Brandicourt named Sanofi's next CEO

Four months after the ouster of former Sanofi CEO Chris Viehbacher, the company has decided to hire a pharma veteran. But just how much power will Brandicourt have?

By Nicole Gray , Sy Mukherjee • Feb. 19, 2015

The more, the merrier? Endo also pursuing Salix Pharma bid

On top of Valeant and Shire.

By Nicole Gray • Feb. 18, 2015

Can AZ finally solidify a deal for its anti-infectives unit?

For more than a year, AstraZeneca has been shopping a partnership deal for its anti-infectives unit. But there don't seem to be any takers—and the clock is ticking.

By Nicole Gray • Feb. 17, 2015

Valeant arranges financing for potential Salix Pharma bid

Now that Valeant has secured sufficient funding, it is better positioned to make a bid for gastroenterology-focused Salix Pharmaceuticals.

By Nicole Gray • Feb. 13, 2015

Indian pharma giants scuffle to snap up injectables maker Claris

Claris Lifesciences, based in Ahmedabad, focuses on generic sterile injectables—an area where demand currently outweighs supply.

By Nicole Gray • Feb. 13, 2015

Shire raises 2015 forecast on NPS acquisition

After striking a $5.2 billion deal for NJ-based NPS Pharma last month, Shire, which is based in Ireland, is forecasting growth in the 5% to 9% range.

By Nicole Gray • Feb. 12, 2015

Hospira CEO's golden parachute for Pfizer deal: $80 million

That includes stock options and tax payments.

By Sy Mukherjee • Feb. 12, 2015

GSK broadens vax portfolio with $190M GlycoVaxyn deal

This is on top of a $5.25 billion vaccine deal with Novartis.

By Nicole Gray • Feb. 12, 2015

Gilead to open London HQ, double UK workforce

The new HQ will cost $19.6 million. 

By Sy Mukherjee • Feb. 10, 2015

BIO survey finds more series A VC funding for fewer recipients

A venture capital funding survey conducted by the Biotechnology Industry Organization (BIO) revealed several paradoxes, but also encouraging insight into how series A funding is driving start-ups.

By Nicole Gray • Feb. 10, 2015

Pfizer may still be hungry after Hospira deal

Pfizer's recent $15 billion acquisition of Hospira has led to speculation that the company is on the acquisition hunt.

By Nicole Gray • Feb. 9, 2015

Isis earns $10 million milestone from Biogen Idec

If ever there were a productive partnership, Biogen Idec and Isis Pharma have it.

By Nicole Gray • Feb. 6, 2015

NY Attorney General nabs price reduction for heroin-fighting naloxone

The price of naloxone, which is used as a heroin antidote, doubled last fall, putting tremendous pressure on health officials who treat addicts.

By Nicole Gray • Feb. 6, 2015

Trans-Pacific Partnership trade talks fail to resolve patent & IP issues

The U.S. wants 12 years of protection. Emerging markets want about seven. Can negotiators bridge the gap?

By Nicole Gray • Feb. 5, 2015

Valeant reportedly considering Salix acquisition

After a period of inventory-accounting restatement and management upheaval, Valeant is ready to hit the acquisition trail again.

By Nicole Gray • Feb. 4, 2015

Valeant to make $296M 'stalking horse' bid on Seattle-based Dendreon

Dendreon, which has slid into chapter 11 and is best known as the proprietor of prostate cancer treatment Provenge, is on the bidding block, and Valeant is a top bidder.

By Nicole Gray • Feb. 2, 2015

Alexion COO Hallal named company's next CEO

The departing CEO, Dr. Leonard Bell, will continue to serve as chairman of the board of directors.

By Nicole Gray • Jan. 30, 2015

Express Scripts claims it's saved US healthcare $4B through hep C deals

It's a bold statement. But does the math add up?

By Nicole Gray • Jan. 29, 2015

Largest US health insurer latest to give Harvoni preferred hep C drug status

Another win for Gilead—and a loss for AbbVie—as UnitedHealth, the nation's largest health insurer, gives Harvoni preferred status for all insured customers. 

By Nicole Gray • Jan. 29, 2015

Gilead to launch generic Sovaldi in India this summer

Gilead has been working with India's health ministry to find a workable solution to the problem of distributing generic Sovaldi (sofosbuvir) at an accessible price.

By Nicole Gray • Jan. 28, 2015

Actavis to buy Auden McKenzie for $465M

The acquisition of Auden McKenzie will make Actavis the largest supplier of generics in the United Kingdom.

By Nicole Gray • Jan. 28, 2015

Hindsight: Valeant CEO admits mistakes in approach to Allergan bid

Michael Pearson, CEO of Valeant, also said his firm would no longer be teaming up with activist investor Bill Ackman in acquisition quests.

By Nicole Gray • Jan. 23, 2015

REPORT: Takeda COO Weber approached for vacant Sanofi CEO post

But Christophe Weber is reportedly not interested in the position. 

By Sy Mukherjee • Jan. 22, 2015